TriangleNCT04256707 · OUTCOME
Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- hours
- Interval / dispersion
- Full Range
- Time frame
- Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
What was measured
Tmax was defined as time to the maximum observed concentration of selinexor.
Analysis population: PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication).
Groups in this outcome
Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function
Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.
Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function
Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.
Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function
Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.
Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
Participants with severe hepatic function received Tablet A (selinexor 2 x 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.
| Group | Source count |
|---|---|
| Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | 19 |
| Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | 19 |
| Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | 7 |
| Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | 4.00 | Not reported | 1.58 | 9.92 | Not reported |
| Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | 2.92 | Not reported | 0.25 | 5.83 | Not reported |
| Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | 5.93 | Not reported | 1.45 | 10.00 | Not reported |
| Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function | 5.08 | Not reported | 3.08 | 7.75 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.58
- upper Limit
- 9.92
- value
- 4.00
- group Id
- OG001
- lower Limit
- 0.25
- upper Limit
- 5.83
- value
- 2.92
- group Id
- OG002
- lower Limit
- 1.45
- upper Limit
- 10.00
- value
- 5.93
- group Id
- OG003
- lower Limit
- 3.08
- upper Limit
- 7.75
- value
- 5.08
- denoms
- counts
- group Id
- OG000
- value
- 19
- group Id
- OG001
- value
- 19
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 6
- units
- Participants
- description
- Tmax was defined as time to the maximum observed concentration of selinexor.
- dispersion Type
- Full Range
- groups
- description
- Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.
- id
- OG000
- title
- Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function
- description
- Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.
- id
- OG001
- title
- Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function
- description
- Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.
- id
- OG002
- title
- Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function
- description
- Participants with severe hepatic function received Tablet A (selinexor 2 x 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.
- id
- OG003
- title
- Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function
- param Type
- MEDIAN
- population Description
- PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication).
- reporting Status
- POSTED
- time Frame
- Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
- title
- Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
- type
- SECONDARY
- unit Of Measure
- hours
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice